These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25082785)

  • 21. Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia.
    Wu X; Wang F; Yang X; Gong Y; Niu T; Chu B; Qu Y; Qian Z
    Small; 2024 Oct; 20(42):e2403409. PubMed ID: 38934349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
    Laing AA; Harrison CJ; Gibson BES; Keeshan K
    Exp Hematol; 2017 Oct; 54():40-50. PubMed ID: 28668350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept.
    Valent P
    Curr Cancer Drug Targets; 2011 Jan; 11(1):56-71. PubMed ID: 21062243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.
    Carter JL; Hege K; Yang J; Kalpage HA; Su Y; Edwards H; Hüttemann M; Taub JW; Ge Y
    Signal Transduct Target Ther; 2020 Dec; 5(1):288. PubMed ID: 33335095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukemia stem cells in acute myeloid leukemia.
    Chan WI; Huntly BJ
    Semin Oncol; 2008 Aug; 35(4):326-35. PubMed ID: 18692683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concise Review: Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit.
    Zhang H; Li S
    Stem Cells Transl Med; 2019 Aug; 8(8):768-774. PubMed ID: 31016860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.
    Ghosh J; Kapur R
    Exp Hematol; 2017 Jun; 50():13-21. PubMed ID: 28342808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel drug therapies in myeloid leukemia.
    Horne GA; Kinstrie R; Copland M
    Pharm Pat Anal; 2015; 4(3):187-205. PubMed ID: 26030080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New approaches to target leukemia stem cells].
    Takenaka K; Akashi K
    Nihon Rinsho; 2014 Jun; 72(6):1018-25. PubMed ID: 25016798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New molecular concepts and targets in acute myeloid leukemia.
    Buzzai M; Licht JD
    Curr Opin Hematol; 2008 Mar; 15(2):82-7. PubMed ID: 18300752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
    McMahon CM; Perl AE
    Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?
    Bernasconi P; Farina M; Boni M; Dambruoso I; Calvello C
    Am J Hematol; 2016 May; 91(5):507-17. PubMed ID: 26822317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms.
    Griessinger E; Anjos-Afonso F; Pizzitola I; Rouault-Pierre K; Vargaftig J; Taussig D; Gribben J; Lassailly F; Bonnet D
    Stem Cells Transl Med; 2014 Apr; 3(4):520-9. PubMed ID: 24493855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
    Carter BZ; Mak DH; Cortes J; Andreeff M
    Semin Hematol; 2010 Oct; 47(4):362-70. PubMed ID: 20875553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.
    Walter RB; Appelbaum FR; Estey EH; Bernstein ID
    Blood; 2012 Jun; 119(26):6198-208. PubMed ID: 22286199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
    Tavakkoli M; Chung SS; Park CY
    Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.
    Bruserud Ø; Aasebø E; Hernandez-Valladares M; Tsykunova G; Reikvam H
    Expert Opin Drug Discov; 2017 Oct; 12(10):1053-1065. PubMed ID: 28748730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.
    Hassane DC; Guzman ML; Corbett C; Li X; Abboud R; Young F; Liesveld JL; Carroll M; Jordan CT
    Blood; 2008 Jun; 111(12):5654-62. PubMed ID: 18305216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.